Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex versus Lucentis in branch retinal vein occlusion
2010-023900-29Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in branch retinal vein occlusion (BRVO) and macular edema comparing Ozurdex arm with Lucentis arm (2 arms). Primary endpoint: Change in best-corrected visual acuity at 12 months. Started Jun 2011; status: completed.
02
Drugs
ozurdexranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on 2010-023900-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023900-29.